Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Geriatrics (Basel) ; 9(2)2024 Mar 14.
Artigo em Inglês | MEDLINE | ID: mdl-38525754

RESUMO

INTRODUCTION: Adopting healthy lifestyle behaviors has the potential to slow cognitive decline in older adults by reducing risks associated with dementia. Curriculum-based group health coaching may aid in establishing behavior change centered for dementia risk factors. METHODS: In this pilot clinical care patient group study (n = 6), we examined the effects of a six-month online Cognitive Health Program combined with a weekly telehealth support group led by the course creator, and personalized health optimization by a collaborating physician, in older adults with subjective cognitive decline. Cognition was assessed at baseline and post-intervention using a computerized battery. RESULTS: Cognitive changes were estimated with nonparametric tests and effect sizes (Cohen's d). Results showed significant improvements in global cognition (p < 0.03, d = 1.6), spatial planning (p < 0.01, d = 2.3), and visuospatial processing (p < 0.05, d = 1.1) compared to baseline. Participants reported high levels of satisfaction with the virtual group format and online curriculum. CONCLUSIONS: This small pilot study suggests that a virtual six-month personalized health coaching group with self-paced online health education is feasible and potentially efficacious for improving cognition in participants with subjective cognitive complaints. This format may facilitate behavior change to slow cognitive decline. Future studies should include a control group, a larger, more diverse sample as well as assessing mood and other subjective measures.

2.
J Am Nutr Assoc ; 41(1): 116-124, 2022 01.
Artigo em Inglês | MEDLINE | ID: mdl-33507846

RESUMO

Hibiscus sabdariffa, this beverage has been used for millennia as both a delicious cultural beverage and an ancient medicinal therapy. In recent years, many studies have investigated the uses and mechanisms of action of Hibiscus sabdariffa to treat common chronic diseases. In this literature review, we place the spotlight on Hibiscus sabdariffa's medical effect on common chronic diseases, the flower commonly used to make hibiscus tea. The databases PubMed, MEDLINE, Clinical Key, and CINAHL were searched for studies related to Hibiscus sabdariffa's compounds, antioxidative and anti-inflammatory features, mechanism of action on common chronic diseases including hypertension, hyperlipidemia, obesity, diabetes, and Alzheimer's disease. Hibiscus sabdariffa antihypertensive potentials originate from the vasodilator activity, diuretic efficacy, functionality as an ACE inhibitor, adipocyte differentiation inhibitor, heart rate reduction ability, and anti-inflammatory mechanistic. The antihyperlipidemic effect is dose-dependent and stems from the antioxidative effect and the activation of AMPK through phosphorylation and the inhibition of regulatory adipogenic transcription factors PPAR-γ, C/EBP-α, and SREBP-1c, which altogether results in lipid-lowering effect. As an antihyperglycemic, Hibiscus sabdariffa serves as anti-insulin resistance by inhibition of the phosphorylation of IRS-1 beside a similar effect to gliptins. Finally, Hibiscus sabdariffa was proven to protect against neuroinflammation in microglial cell culture exposed to LPS by decreasing IL-1, IL-6, TNF-α expression, and the protective effect against glucotoxicity, improve memory function by inhibiting the formation of hyperphosphorylated tau proteins in the mouse brain. Regular consumption of hibiscus tea or extract is beneficial for a reduction in chronic disease risk and diagnosis.Key teaching pointsHibiscus sabdariffa, or hibiscus, has been used for millennia as both a delicious cultural beverage and an ancient medicinal therapy. Recent studies have investigated the uses of Hibiscus sabdariffa to treat common chronic diseases.Its antihypertensive potential originates from the vasodilator activity, diuretic efficacy, functionality as an ACE inhibitor, adipocyte differentiation inhibitor, heart rate reduction ability, and anti-inflammatory mechanistics.The antihyperlipidemic effect is dose-dependent and stems from the antioxidative effect and the activation of AMPK through phosphorylation and also the inhibition of regulatory adipogenic transcription factors PPAR-γ, C/EBP-α and SREBP-1c which all together results in lipid-lowering effect.As an antihyperglycemic, Hibiscus sabdariffa serves as anti-insulin resistance by inhibition of the phosphorylation of IRS-1 beside the similar effect to gliptins.Hibiscus sabdariffa was proven to protect against neuroinflammation in microglial cell culture exposed to LPS by decreasing IL-1, IL-6, TNF-α expression, and the protective effect against glucotoxicity, improve memory function by inhibiting the formation of hyperphosphorylated tau proteins in the mouse brain.


Assuntos
Inibidores da Dipeptidil Peptidase IV , Essências Florais , Hibiscus , Proteínas Quinases Ativadas por AMP , Inibidores da Enzima Conversora de Angiotensina , Animais , Anti-Hipertensivos/uso terapêutico , Antioxidantes , Doença Crônica , Diuréticos , Hipoglicemiantes , Hipolipemiantes , Interleucina-1 , Interleucina-6 , Lipopolissacarídeos , Camundongos , Receptores Ativados por Proliferador de Peroxissomo , Extratos Vegetais/farmacologia , Proteína de Ligação a Elemento Regulador de Esterol 1 , Chá , Fator de Necrose Tumoral alfa , Vasodilatadores/uso terapêutico , Proteínas tau
3.
Ann Med ; 53(1): 1673-1675, 2021 12.
Artigo em Inglês | MEDLINE | ID: mdl-34555991

RESUMO

In the setting of the raging COVID-19 pandemic, the search for innovative therapeutics is desperately sought after. As we learn more about the characteristics and metabolic health of patients and as our understanding of COVID-19 pathophysiology and treatment progresses, so is our understanding of medication effects that might increase disease severity. As of late, ACE inhibitors have been under investigation for a potential increase in illness severity due to ACE2 upregulation. Given our knowledge of other nutrient-pharmaceutical interactions, could the ACE inhibitor impact on COVID be due to something else? In this paper, we discuss the possibility that ACE inhibitors might be affecting COVID-19 patients by causing zinc insufficiency.KEY MESSAGESZinc deficiency caused by chronic ACE inhibitor usage may exacerbate the pathogenicity of COVID-19 in susceptible patients.A multi-center study is needed to assess the zinc levels of patients with COVID-19 who are taking ACE inhibitors and other medications that may result in low zinc levels.


Assuntos
Enzima de Conversão de Angiotensina 2/metabolismo , Inibidores da Enzima Conversora de Angiotensina/efeitos adversos , Tratamento Farmacológico da COVID-19 , Zinco/deficiência , Enzima de Conversão de Angiotensina 2/efeitos dos fármacos , Inibidores da Enzima Conversora de Angiotensina/administração & dosagem , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , COVID-19/diagnóstico , COVID-19/epidemiologia , COVID-19/virologia , Interações Medicamentosas , Feminino , Humanos , Masculino , Estado Nutricional/efeitos dos fármacos , Preparações Farmacêuticas , Fatores de Risco , SARS-CoV-2/genética , Índice de Gravidade de Doença , Zinco/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA